Johnson & Johnson (NYSE:JNJ) is Abacus FCF Advisors LLC's 8th Largest Position

Abacus FCF Advisors LLC lowered its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 3.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 106,247 shares of the company's stock after selling 3,383 shares during the period. Johnson & Johnson comprises 2.8% of Abacus FCF Advisors LLC's holdings, making the stock its 8th largest position. Abacus FCF Advisors LLC's holdings in Johnson & Johnson were worth $17,620,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. WealthTrak Capital Management LLC purchased a new position in Johnson & Johnson in the fourth quarter worth $26,000. Mountain Hill Investment Partners Corp. bought a new stake in shares of Johnson & Johnson in the fourth quarter valued at $29,000. Conquis Financial LLC bought a new stake in shares of Johnson & Johnson in the fourth quarter valued at $33,000. Bernard Wealth Management Corp. bought a new stake in shares of Johnson & Johnson in the fourth quarter valued at $36,000. Finally, Runnymede Capital Advisors Inc. bought a new stake in shares of Johnson & Johnson in the fourth quarter valued at $38,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Price Performance

NYSE JNJ traded up $0.24 during trading on Friday, reaching $156.90. The company's stock had a trading volume of 6,587,488 shares, compared to its average volume of 7,963,253. The stock has a market capitalization of $377.52 billion, a PE ratio of 23.59, a P/E/G ratio of 2.56 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The firm has a fifty day moving average of $153.84 and a 200 day moving average of $153.72. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. The business had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. Analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were issued a $1.30 dividend. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.31%. The ex-dividend date of this dividend was Tuesday, May 27th. Johnson & Johnson's dividend payout ratio is presently 57.84%.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Bank of America lowered their target price on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a research note on Thursday, April 10th. Sanford C. Bernstein restated a "market perform" rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Royal Bank of Canada restated an "outperform" rating and issued a $181.00 target price on shares of Johnson & Johnson in a research note on Thursday, June 5th. Barclays decreased their price objective on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 17th. Finally, Wall Street Zen lowered Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 22nd. Eleven equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson has an average rating of "Moderate Buy" and a consensus target price of $170.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.